

We claim:

1. A method for treating an acute or chronic inflammatory disease which comprises administering to
5 a patient in need thereof therapeutically effective amounts of a TNF binding protein and at least one additional anti-inflammatory drug, wherein said TNF binding protein and additional anti-inflammatory drug are administered separately or in combination.
10
2. The method of claim 1 wherein the anti-inflammatory drug is methotrexate (N-[4-[[2,4-diamino-6-pteridiny]methylamino]benzoyl]-L-glutamic acid).
- 15 3. The method of claim 1 wherein the anti-inflammatory drug is a *fas* fusion protein.
4. The method of claim 1, wherein said TNF binding protein is wherein said TNF binding protein is
20 sTNFR-I, sTNFR-II, sTNFR fragments or sTNFR Fc.
5. The method of any one of claims 1 through 4, wherein said inflammatory disease is an inflammatory disease of a joint.
25
6. The method of claim 5, wherein said inflammatory disease of a joint is rheumatoid arthritis.
- 30 7. The method of claim 3, wherein said TNF binding protein and said methotrexate are administered in a pharmaceutically acceptable carrier.
8. The method of claim 3, wherein said TNF
35 binding protein and said *fas* fusion protein are administered in a pharmaceutically acceptable carrier.

5

5

25

35

30

18. The use according to claims 15 through 17 wherein said methotrexate is administered orally, intraperitoneally, subcutaneously or intravenously.

5 19. The use according to claims 15 through 17 wherein said methotrexate is administered orally.

10 20. The use of Claim 15, wherein the anti-inflammatory drug is a *fas* fusion protein.

15 21. A use of a TNF binding protein in the preparation of a medicament for treating an acute or chronic inflammatory disease in a mammal in combination with the administration of an additional anti-inflammatory drug.

 22. The use of according to Claim 21, wherein the anti-inflammatory drug is methotrexate.

20 23. The use according to claims 20 through 22 wherein said methotrexate is administered orally, intraperitoneally, subcutaneously or intravenously.

25 24. The use of according to Claim 21, wherein the anti-inflammatory drug is a *fas* fusion protein.

30 25. The use according to claims 21 through 24 wherein the TNF binding protein is sTNFR-I, sTNFR-II, sTNFR fragments or sTNFR Fc.

 26. The use according to Claims 21 through 25 wherein the TNF binding protein in the medicament is present in an amount of up to about 200 mg.